论文信息 - Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1{alpha}. - 字舞流文

Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1{alpha}.

R. Herbst | R. Kurzrock | G. Weiss | R. Tibes | D. V. Hoff | G. Falchook | L. Pestano | A. Lowe | T. Iyengar